June 2019 News & Views: Educational Affairs Committee Plans Nexus 2019; Cathy Carroll Fund Now Receiving Donations; Cantrell Quoted in Washington Post; AMCP Releases Concepts for Effective PA Practices
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to comment on its public hearing on Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products [FDA-2019-N-1132].
As stakeholders that support patient access to affordable medicines and competition in the pharmaceutical marketplace, we applaud the Food and Drug Administration’s (FDA) efforts to foster the development of biosimilar medicines for America’s patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the updated draft industry guidance on “Nonproprietary Naming of Biological Products” published in the Federal Register on March 8, 2019. AMCP appreciates FDA’s ongoing efforts to issue and update guidance that allow health care providers to safely and effectively use biosimilar products.
May 2019 News & Views: Survey Identifies Barriers and Solutions to Biosimilar Adoption; In Memoriam: Past President Cathy Carroll; CEO Blog: PAs Play Key Role in Appropriate Medication Use; PGY1 Residents First to Rotate at AMCP/Foundation Headquarters
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services Office of Inspector General (HHS-OIG) for the opportunity to provide comments in response to the proposed rule titled “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of a New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees [OIG-0936-P]” published in the Federal Register on February 6, 2019.